Founded in 2002, AAA has a legacy as a pioneer in the development and delivery of radiopharmaceutical drugs for diagnostic imaging. More recently, AAA has focused its efforts on developing targeted radioligand therapies and precision imaging diagnostics that target specific markers that are over-expressed by certain types of solid tumors. AAA currently employs more than 1,100 associates across 31 sites in 12 countries; with 19 manufacturing facilities in 8 countries and 6 research and development sites.